21
2021-10
Suzhou, October 21 , 2021 — 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021.
11
2021-10
Suzhou, October 11 , 2021 — 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the clinical trial of ALK-1 antibody (GT90001C) and Nivolumab (Opdivo®) combination therapy for the treatment of systemic therapy naïve patients with advanced hepatocellular carcinoma (“HCC”) was approved by the National Medical Products Administration (the “NMPA”) of China on October 9, 2021.
04
2021-10
Suzhou, October 4 , 2021 — 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that on October 1 its phase III clinical trial of proxalutamide for the treatment of hospitalized COVID-19 patients has enrolled and dosed its first patient in the United States. Proxalutamide is the only small-molecule oral drug which has entered the phase III MRCT clinical trial for treating hospitalized COVID-19 patients.
26
2021-09
Suzhou, September 26, 2021 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that on September 22 the Brazilian Health Regulatory Agency (ANVISA) granted an approval for the phase III clinical trial of proxalutamide to treat hospitalized COVID-19 patients. This is the third ANVISA-approved pivotal study sponsored by Kintor Pharma for the treatment of COVID-19 patients with proxalutamide.
08
2021-09
Suzhou, September 8, 2021 - 真人直营投注网站 (“Kintor Pharma”, HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of pyrilutamide ("KX-826", tincture) in China for the treatment of androgenetic alopecia (AGA) was met, which was statistically significant and clinically meaningful.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn